Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapy.

Autor: Doornhof KR; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands., van der Linden PD; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands., Boeke GM; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands., Willemsen AECAB; Department of Internal Medicine, Tergooi Medical Center, Hilversum, The Netherlands., Daskapan A; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands. a.daskapan@gmail.com.
Jazyk: angličtina
Zdroj: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2023 Apr; Vol. 79 (4), pp. 493-501. Date of Electronic Publication: 2023 Feb 09.
DOI: 10.1007/s00228-023-03466-8
Abstrakt: Purpose: The primary objective of this study was to determine if dihydropyrimidine dehydrogenase (DPD) activity measured in peripheral blood mononuclear cells (PBMCs) is related to adverse events during fluoropyrimidine therapy.
Methods: A retrospective cohort study was conducted. The study population included 481 patients who received fluoropyrimidine treatment and for whom relevant patient characteristics were known and adverse events were noted in the electronic health records. Factors besides DPD phenotype that could affect the incidence of adverse events were corrected for using log regression. These log regression models were used to identify an association between the DPD phenotype measured in PBMCs and adverse events.
Results: Patients with a decreased DPD activity measured in PBMCs suffered more adverse events. Results from log regression data show that this effect remains significant after correcting for dosage, chemotherapy regimen and relevant patient characteristics.
Conclusion: A significant correlation was found between reduced DPD enzyme activity in PBMCs and adverse events. The findings in this paper support further exploring DPD phenotyping as a method for preventing fluoropyrimidine-related adverse events. Further assessment of DPD phenotyping will require clinical validation in a prospective study.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: